WebDec 1, 2024 · The ExTINGUISH Trial will randomize 116 participants with moderate-to-severe NMDAR encephalitis to receive either inebilizumab or placebo in addition to first-line therapies. Inebilizumab is a promising therapeutic monoclonal antibody for the treatment of NMDAR encephalitis. WebThe ExTINGUISH Trial will prospectively study an optimized B-cell depletion therapy to promote better long-term outcomes in NMDAR encephalitis, to determine more meaningful cognitive endpoints, and to identify better biologic biomarkers to predict outcome. Eligibility You can join if... Inclusion Criteria: Inclusion Criteria 1.

The ExTINGUISH Trial for NMDAR Encephalitis

WebDec 10, 2024 · NeuroNEXT is the Network for Excellence in Neuroscience Clinical Trials. It is a National Institute of Neurological Disorders and Stroke (NINDS) initiative to conduct … WebThe ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis (ExTINGUISH) ... Double-Blind, Randomized Controlled Trial to Evaluate the Activity and Safety of Inebilizumab in Anti-Nmda Receptor Encephalitis and Assess Markers of Disease : Secondary IDs: Study Status. Record Verification: July 2024 : Overall Status: Not yet recruiting: Study Start ... francisthemage

Inebilizumab as a Potential Therapy for Autoimmune Encephalitis ...

WebDr. Clardy will discuss the ExTINGUISH Trial, a randomized controlled trial of Inebilizumab for anti-NMDAR Encephalitis, framed in the context of learning about the NIH … WebFeb 23, 2024 · The phase 2 ExTINGUISH trial (NCT04372615), will assess safety and efficacy in 300 mg doses of inebilizumab (as a therapy for moderate-to-severe NMDAR encephalitis. 1 One-hundred and twenty patients are to be enrolled from 22 sites (United States, n = 20; Europe, n = 2), and patients will receive standard “first-line” … WebThe ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis (ExTINGUISH) Overview Study type Interventional Study phase 2 Study IDs About this study The purpose of this … blank texas w9